FDA Safety Review of Mifepristone Extended Into Next Year, Court Filing Shows
The Food and Drug Administration (FDA) has stated that its safety review of the nation's primary abortion pill, mifepristone, will continue into next year. The agency provided this update in a court filing, indicating that a report on the review's…
Rochester, NY, October 8, 2026 — The Food and Drug Administration (FDA) has indicated that its ongoing safety review of mifepristone, a medication frequently used in abortions, will extend into the following year. This update was shared by the agency within a court filing.
According to the filing, the FDA anticipates releasing a report detailing the findings of its safety review by March 2027. The duration of this review process means its conclusion will occur beyond the immediate future.
This development takes place against a backdrop of continuous legal challenges that question the availability and regulatory status of mifepristone. The drug’s accessibility has been a subject of significant legal contention.
The specific details or outcomes of the ongoing safety review, beyond its extended timeline, were not elaborated upon in the provided information. The contractor’s name involved in the review was not provided. The fine amount was not provided.
Story summarized from the original created by Kiley Wren on www.whec.com, see more information here.
Media gallery
